Berkeley Capital Partners LLC raised its holdings in Astrazeneca PLC (NYSE:AZN) by 22.2% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 42,346 shares of the company’s stock after purchasing an additional 7,702 shares during the period. Astrazeneca PLC accounts for approximately 1.0% of Berkeley Capital Partners LLC’s portfolio, making the stock its 20th largest holding. Berkeley Capital Partners LLC’s holdings in Astrazeneca PLC were worth $1,435,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in AZN. Nuveen Asset Management LLC purchased a new stake in shares of Astrazeneca PLC in the first quarter valued at about $225,000. Meeder Asset Management Inc. purchased a new position in shares of Astrazeneca PLC during the second quarter valued at approximately $105,000. OLD National Bancorp IN purchased a new position in shares of Astrazeneca PLC during the second quarter valued at approximately $201,000. BB&T Corp lifted its stake in shares of Astrazeneca PLC by 5.8% during the second quarter. BB&T Corp now owns 144,551 shares of the company’s stock valued at $4,928,000 after buying an additional 7,960 shares during the period. Finally, Huntington National Bank lifted its stake in shares of Astrazeneca PLC by 88.0% during the second quarter. Huntington National Bank now owns 5,475 shares of the company’s stock valued at $187,000 after buying an additional 2,562 shares during the period. 14.44% of the stock is currently owned by institutional investors.

Astrazeneca PLC (AZN) traded down $0.13 during trading on Monday, hitting $33.33. 979,910 shares of the stock traded hands, compared to its average volume of 4,805,815. Astrazeneca PLC has a 52 week low of $25.55 and a 52 week high of $35.60. The firm has a market capitalization of $83,090.00, a price-to-earnings ratio of 7.99, a P/E/G ratio of 3.16 and a beta of 0.79. The company has a quick ratio of 0.72, a current ratio of 0.94 and a debt-to-equity ratio of 1.09.

Astrazeneca PLC (NYSE:AZN) last released its quarterly earnings data on Thursday, November 9th. The company reported $1.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.57 by $0.55. Astrazeneca PLC had a net margin of 15.90% and a return on equity of 34.02%. The company had revenue of $6.23 billion during the quarter, compared to analyst estimates of $6 billion. During the same quarter in the prior year, the business earned $1.32 earnings per share. The business’s quarterly revenue was up 9.4% compared to the same quarter last year. sell-side analysts forecast that Astrazeneca PLC will post 1.93 earnings per share for the current fiscal year.

WARNING: “Berkeley Capital Partners LLC Acquires 7,702 Shares of Astrazeneca PLC (AZN)” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2017/11/20/berkeley-capital-partners-llc-acquires-7702-shares-of-astrazeneca-plc-azn.html.

AZN has been the topic of several recent analyst reports. BMO Capital Markets initiated coverage on shares of Astrazeneca PLC in a research note on Wednesday, September 6th. They set an “outperform” rating and a $38.00 price objective on the stock. Sanford C. Bernstein raised shares of Astrazeneca PLC from a “market perform” rating to an “outperform” rating and upped their price objective for the company from $30.00 to $39.00 in a research note on Friday, September 22nd. Leerink Swann downgraded shares of Astrazeneca PLC from an “outperform” rating to a “market perform” rating and reduced their price objective for the company from $36.00 to $31.00 in a research note on Thursday, July 27th. Natixis raised shares of Astrazeneca PLC from a “neutral” rating to a “buy” rating in a research note on Wednesday, September 6th. Finally, Argus reissued a “buy” rating and set a $35.00 price objective on shares of Astrazeneca PLC in a research note on Friday, September 1st. Four research analysts have rated the stock with a sell rating, eight have given a hold rating and twelve have issued a buy rating to the company. The company has an average rating of “Hold” and an average price target of $34.20.

Astrazeneca PLC Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Astrazeneca PLC (NYSE:AZN).

Institutional Ownership by Quarter for Astrazeneca PLC (NYSE:AZN)

Receive News & Stock Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related stocks with our FREE daily email newsletter.